中东和非洲病毒载体纯化市场 – 行业趋势和 2028 年预测

请求目录 请求目录 与分析师交谈 与分析师交谈 立即购买 立即购买 购买前请咨询 提前咨询 免费样本报告 免费样本报告

中东和非洲病毒载体纯化市场 – 行业趋势和 2028 年预测

  • Healthcare
  • Published Report
  • May 2021
  • MEA
  • 350 页面
  • 桌子數: 147
  • 图号: 42

>中东和非洲病毒载体纯化市场,按产品和服务(产品和服务)、类型(逆转录病毒载体、疫苗病毒、腺病毒载体、腺相关病毒载体、慢病毒等)、工作流程(上游处理和下游处理)、纯化技术(密度梯度超速离心、超滤、沉淀、两相萃取系统和色谱法)、运营规模(临床前/临床和商业)、递送方式(体内和体外)、疾病适应症(癌症、遗传性疾病、传染病、兽医疾病等)、应用(反义和 RNAi、基因治疗、细胞治疗和疫苗学)、最终用户(生物技术公司、制药公司、合同研究组织、合同开发和制造组织 (CDMO) 和学术/研究机构)、国家(沙特阿拉伯、南非、阿联酋、以色列、埃及和中东和非洲其他地区)行业趋势和预测2028 

中东和非洲病毒载体纯化市场市场分析和洞察:中东和非洲病毒载体纯化市场

病毒载体纯化市场预计将在 2021 年至 2028 年的预测期内实现市场增长。Data Bridge Market Research 分析称,在 2021 年至 2028 年的预测期内,该市场以 12.4% 的复合年增长率增长,预计到 2028 年将达到 2217 万美元。对病毒载体的需求不断增长,成为病毒载体纯化市场发展的驱动力

分子生物学家经常使用病毒载体将遗传物质传递到细胞中。这个过程可以在体内(活体生物体内)或细胞培养(体外)中进行。病毒已经发展出专门的分子机制,可以有效地将其基因组运送到它们感染的细胞内。转导是通过载体传递基因或其他遗传物质,被感染的细胞被称为转导细胞。

COVID-19 的出现和对病毒疫苗的需求正在推动病毒载体纯化市场的发展。缺乏可扩展性是病毒载体纯化市场的一个制约因素。传染病数量的增加为病毒载体纯化市场带来了机遇。技术人员的短缺是病毒载体纯化市场面临的挑战。

病毒载体纯化市场报告提供了市场份额、新发展和产品线分析、国内和本地市场参与者的影响的详细信息,分析了新兴收入领域、市场法规变化、产品审批、战略决策、产品发布、地域扩张和市场技术创新方面的机会。要了解分析和病毒载体纯化市场情景,请联系 Data Bridge Market Research 获取分析师简报,我们的团队将帮助您创建收入影响解决方案以实现您的预​​期目标。

中东和非洲病毒载体纯化市场病毒载体纯化市场范围和市场规模

病毒载体纯化市场根据产品和服务、类型、工作流程、纯化技术、操作规模、交付方式、疾病指征、应用和最终用户分为九个值得注意的细分市场。细分市场之间的增长有助于您分析利基增长领域和进入市场的策略,并确定您的核心应用领域和目标市场的差异。

  • 根据产品和服务,病毒载体纯化市场分为产品和服务。2021 年,由于有多种创新的载体纯化解决方案可供选择,预计产品部门将主导病毒载体纯化市场。
  • 根据类型,病毒载体纯化市场细分为逆转录病毒载体、疫苗病毒、腺病毒载体、腺相关病毒载体、慢病毒和其他。由于 AAV 的传染性范围广泛,预计 2021 年腺相关病毒载体将主导病毒载体纯化市场。
  • 根据工作流程,病毒载体纯化市场分为上游加工和下游加工。预计 2021 年上游加工领域将主导病毒载体纯化市场,因为使用此工艺生产的病毒载体可以在转染后短时间内从细胞中收获。
  • 根据纯化技术,病毒载体纯化市场细分为密度梯度超速离心、超滤、沉淀、两相萃取系统和色谱法。2021 年,色谱法预计将主导病毒载体纯化市场,因为它已广泛用于疫苗和基因治疗载体的纯化。
  • 根据运营规模,病毒载体纯化市场分为临床前/临床和商业。由于主要医疗保健组织对研发活动的投资不断增加,预计 2021 年临床前/临床部分将主导病毒载体纯化市场。
  • 根据递送方式,病毒载体纯化市场分为体内和体外。2021 年,体内纯化预计将占据病毒载体纯化市场的主导地位,因为其可用性高且工艺可靠。
  • 根据疾病适应症,病毒载体纯化市场细分为癌症、遗传性疾病、传染病、兽医疾病和其他疾病。由于遗传性疾病的发病率和患病率不断上升,预计 2021 年遗传性疾病领域将主导病毒载体纯化市场。
  • 根据应用,病毒载体纯化市场细分为反义和 RNAi、基因治疗、细胞治疗和疫苗学。由于在医疗领域的广泛应用,预计 2021 年基因治疗领域将主导病毒载体纯化市场。
  • 根据最终用户,病毒载体纯化市场分为生物技术公司、制药公司、合同研究组织、合同开发和制造组织 (CDMO) 和学术/研究机构。由于各种医疗组织和政府机构为鼓励研究工作而开展的主动活动不断增加,预计 2021 年学术/研究机构部门将主导病毒载体纯化市场。

中东和非洲 病毒载体纯化市场国家级分析

对中东和非洲病毒载体纯化市场进行了分析,并按国家、产品和服务、类型、工作流程、纯化技术、运营规模、交付方式、疾病指征、应用和最终用户提供了市场规模信息。

中东和非洲病毒载体净化市场报告涉及的国家包括沙特阿拉伯、南非、阿联酋、以色列、埃及以及中东和非洲其他地区。

预计在预测期内,中东和非洲的复合年增长率将达到最快,因为在中东和非洲国家,由于人口迅速增加和医疗支出增加,对病毒载体纯化的需求正在迅速增加。沙特阿拉伯预计将在中东和非洲病毒载体纯化市场占据主导地位,因为沙特阿拉伯是中东和非洲利用先进病毒载体纯化产品进行治疗的领先国家之一。   

报告的国家部分还提供了影响单个市场因素和国内市场监管变化,这些因素和变化会影响市场的当前和未来趋势。新销售、替代销售、国家人口统计、监管法案和进出口关税等数据点是用于预测单个国家市场情景的一些主要指标。此外,在提供国家数据的预测分析时,还考虑了中东和非洲品牌的存在和可用性以及它们因来自本地和国内品牌的激烈或稀少竞争而面临的挑战、销售渠道的影响。 

制造商的战略举措为病毒载体纯化市场参与者创造了新的机会 

病毒载体纯化市场还为您提供每个国家增长的详细市场分析。此外,它还提供有关中东和非洲地区病毒载体纯化市场参与者之间的病毒载体纯化销售、合作伙伴关系、收购、分销协议增长的详细数据。数据适用于 2011 年至 2019 年的历史时期。 

竞争格局和病毒载体纯化市场份额分析

病毒载体纯化市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、生产基地和设施、公司优势和劣势、产品发布、产品试验渠道、产品批准、专利、产品宽度和广度、应用优势、技术生命线曲线。以上提供的数据点仅与公司对中东和非洲病毒载体纯化市场的关注有关。

中东和非洲病毒载体纯化市场报告涵盖的主要参与者包括 Applied Biological Materials Inc.、Creative Biolabs、Bio-Rad Laboratories, Inc.、Merck KGaA、Agilent Technologies, Inc.、Thermo Fisher Scientific Inc.、uniQure NV、BioVision Inc. 以及其他国内参与者。DBMR 分析师了解竞争优势,并为每个竞争对手分别提供竞争分析。

全球各地的公司也签订了许多合同和协议,这也加速了病毒载体纯化市场的发展。 

例如, 

  • 2021年1月,赛默飞世尔科技公司宣布已完成对Novsep在比利时的病毒载体制造业务的收购,这将有助于该公司进一步实现市场多元化。

市场参与者的合作、合资和其他策略正在提升公司在病毒载体纯化市场的形象,这也为组织提高销售增长提供了好处。 


SKU-

Get online access to the report on the World's First Market Intelligence Cloud

  • Interactive Data Analysis Dashboard
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
  • Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Request for Demo

目录

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 TYPE LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.1 VENDOR SHARE ANALYSIS

2.11 MARKET APPLICATION COVERAGE GRID

2.12 SECONDARY SOURCES

2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 MARKET OVERVIEW

4.1 DRIVERS

4.1.1 RISING DEMAND FOR VIRAL VECTORS

4.1.2 AVAILABILITY OF DIVERSE RANGE OF INNOVATIVE SOLUTIONS FOR VECTOR PURIFICATION

4.1.3 EMERGENCE OF COVID-19 AND DEMAND FOR VACCINE DEVELOPMENT

4.1.4 BENEFITS OF VIRAL VECTORS FOR GENE THERAPY

4.1.5 GROWING USAGE OF AAV VECTORS FOR DELIVERY OF SIRNA IN MAMMALIAN CELLS

4.2 RESTRAINTS

4.2.1 LACK OF SCALABILITY

4.2.2 LIMITATIONS OF DOWNSTREAM PURIFICATION

4.3 OPPORTUNITIES

4.3.1 GROWING CANCER BURDEN WORLDWIDE

4.3.2 RISING NUMBER OF INFECTIOUS DISEASES

4.3.3 GROWING GERIATRIC POPULATION

4.3.4 RISING HEALTH CONSCIOUSNESS AND INCREASING SPENDING ON HEALTHCARE

4.4 CHALLENGES

4.4.1 BIOLOGICAL CHALLENGES

4.4.2 SHORTAGE OF SKILLED PERSONNEL

5 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: REGULATIONS

1 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET, BY PRODUCT & SERVICES

1.1 OVERVIEW

1.2 PRODUCTS

1.2.1 RESIN

1.2.2 KIT

1.2.3 REAGENT

1.2.4 PREPACKED COLUMN

1.2.5 CASSETTE

1.2.6 CAPSULE

1.2.7 FILTER PLATE

1.3 SERVICES

2 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET, BY PURIFICATION TECHNIQUE

2.1 OVERVIEW

2.2 CHROMATOGRAPHY

2.2.1 AFFINITY CHROMATOGRAPHY

2.2.2 ION-EXCHANGE CHROMATOGRAPHY

2.2.3 SIZE-EXCLUSION CHROMATOGRAPHY

2.2.4 HYDROPHILIC INTERACTION CHROMATOGRAPHY

2.3 DENSITY-GRADIENT ULTRACENTRIFUGATION

2.4 ULTRAFILTRATION

2.5 PRECIPITATION

2.6 TWO-PHASE EXTRACTION SYSTEMS

3 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET, BY TYPE

3.1 OVERVIEW

3.2 ADENO-ASSOCIATED VIRAL VECTORS

3.3 ADENOVIRAL VECTORS

3.3.1 MASTADENOVIRUS

3.3.2 AVIADENOVIRUS

3.3.3 SIADENOVIRUS

3.3.4 ATADENOVIRUS

3.3.5 ICHTADENOVIRUS

3.4 LENTIVIRUS

3.5 RETROVIRAL VECTORS

3.5.1 REPLICATION DEFECTIVE

3.5.2 REPLICATION-COMPETENT

3.6 VACCINE VIRUS

3.7 OTHER

4 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET, BY WORKFLOW

4.1 OVERVIEW

4.2 UPSTREAM PROCESSING

4.3 DOWNSTREAM PROCESSING

5 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET, BY SCALE OF OPERATION

5.1 OVERVIEW

5.2 PRECLINICAL / CLINICAL

5.3 COMMERCIAL

6 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET, BY DELIVERY MODE

6.1 OVERVIEW

6.2 IN VIVO

6.3 EX VIVO

7 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET, BY DISEASE INDICATION

7.1 OVERVIEW

7.2 GENETIC DISORDERS

7.2.1 THALASSEMIA

7.2.2 CYSTIC FIBROSIS

7.2.3 TAY-SACHS DISEASE

7.2.4 SICKLE CELL ANEMIA

7.2.5 OTHERS

7.3 INFECTIOUS DISEASES

7.3.1 MEASLES VIRUS

7.3.2 VESICULAR STOMATITIS VIRUS

7.3.3 NOVEL ADENOVIRUSES

7.3.4 CYTOMEGALOVIRUS

7.3.5 OTHERS

7.4 VETERINARY DISEASE

7.5 CANCER

7.6 OTHER

8 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET, BY APPLICATION

8.1 OVERVIEW

8.2 GENE THERAPY

8.2.1 RECOMBINANT PROTEIN EXPRESSION

8.2.2 FUNCTIONAL ASSAYS

8.2.3 PROTEIN CHARACTERIZATION

8.2.4 IN VITRO TRANSCRIPTION

8.2.5 OTHERS

8.3 CELL THERAPY

8.4 VACCINOLOGY

8.5 ANTISENSE & RNAI

9 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET, BY END USER

9.1 OVERVIEW

9.2 ACADEMIC/ RESEARCH INSTITUTES

9.3 PHARMACEUTICAL COMPANIES

9.4 CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION (CDMO)

9.5 BIOTECHNOLOGY COMPANIES

9.6 CONTRACT RESEARCH ORGANIZATIONS

10 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET, BY GEOGRAPHY

10.1 MIDDLE EAST & AFRICA

10.1.1 SOUTH AFRICA

10.1.2 SAUDI ARABIA

10.1.3 UAE

10.1.4 EGYPT

10.1.5 ISRAEL

10.1.6 REST OF MIDDLE EAST & AFRICA

11 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: COMPANY LANDSCAPE

11.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA

12 COMPANY PROFILE

12.1 THERMO FISHER SCIENTIFC INC.

12.1.1 COMPANY SNAPSHOT

12.1.2 REVENUE ANALYSIS

12.1.3 COMPANY SHARE ANALYSIS

12.1.4 PRODUCT PORTFOLIO

12.1.5 RECENT DEVELOPMENTS

12.2 CYTIVA (A SUBSIDIARY OF DANAHER)

12.2.1 COMPANY SNAPSHOT

12.2.2 REVENUE ANALYSIS

12.2.3 COMPANY SHARE ANALYSIS

12.2.4 PRODUCT PORTFOLIO

12.2.5 RECENT DEVELOPMENT

12.3 MERCK KGAA

12.3.1 COMPANY SNAPSHOT

12.3.2 REVENUE ANALYSIS

12.3.3 COMPANY SHARE ANALYSIS

12.3.4 PRODUCT PORTFOLIO

12.3.5 RECENT DEVELOPMENT

12.4 AGILENT TECHNOLOGIES, INC.

12.4.1 COMPANY SNAPSHOT

12.4.2 REVENUE ANALYSIS

12.4.3 COMPANY SHARE ANALYSIS

12.4.4 PRODUCT PORTFOLIO

12.4.5 RECENT DEVELOPMENT

12.5 FUJIFILM DIOSYNTH BIOTECHNOLOGIES

12.5.1 COMPANY SNAPSHOT

12.5.2 PRODUCT PORTFOLIO

12.6 ADDGENE

12.6.1 COMPANY SNAPSHOT

12.6.2 PRODUCT PORTFOLIO

12.6.3 RECENT DEVELOPMENT

12.7 ALDEVRON

12.7.1 COMPANY SNAPSHOT

12.7.2 PRODUCT PORTFOLIO

12.7.3 RECENT DEVELOPMENTS

12.8 APPLIED BIOLOGICAL MATERIALS INC.

12.8.1 COMPANY SNAPSHOT

12.8.2 PRODUCT PORTFOLIO

12.8.3 RECENT DEVELOPMENT

12.9 BIA SEPARATIONS

12.9.1 COMPANY SNAPSHOT

12.9.2 PRODUCT PORTFOLIO

12.9.3 RECENT DEVELOPMENTS

12.1 BIO-RAD LABORATORIES, INC.

12.10.1 COMPANY SNAPSHOT

12.10.2 REVENUE ANALYSIS

12.10.3 PRODUCT PORTFOLIO

12.10.4 RECENT DEVELOPMENT

12.11 BIOVISION INC.

12.11.1 COMPANY SNAPSHOT

12.11.2 PRODUCT PORTFOLIO

12.11.3 RECENT DEVELOPMENT

12.12 BATAVIA BIOSCIENCES B.V.

12.12.1 COMPANY SNAPSHOT

12.12.2 PRODUCT PORTFOLIO

12.12.3 RECENT DEVELOPMENT

12.13 CREATIVE BIOGENE

12.13.1 COMPANY SNAPSHOT

12.13.2 PRODUCT PORTFOLIO

12.13.3 RECENT DEVELOPMENTS

12.14 CREATIVE BIOLABS

12.14.1 COMPANY SNAPSHOT

12.14.2 SERVICE PORTFOLIO

12.15 IDT BIOLOGIKA GMBH

12.15.1 COMPANY SNAPSHOT

12.15.2 PRODUCT PORTFOLIO

12.15.3 RECENT DEVELOPMENTS

12.16 PROBIOGEN AG

12.16.1 COMPANY SNAPSHOT

12.16.2 PRODUCT PORTFOLIO

12.16.3 RECENT DEVELOPMENTS

12.17 SIRION-BIOTECH GMBH

12.17.1 COMPANY SNAPSHOT

12.17.2 PRODUCT PORTFOLIO

12.17.3 RECENT DEVELOPMENTS

12.18 TAKARA BIO INC.

12.18.1 COMPANY SNAPSHOT

12.18.2 REVENUE ANALYSIS

12.18.3 PRODUCT PORTFOLIO

12.18.4 RECENT DEVELOPMENTS

12.19 UNIQURE N.V.

12.19.1 COMPANY SNAPSHOT

12.19.2 REVENUE ANALYSIS

12.19.3 PRODUCT PORTFOLIO

12.19.4 RECENT DEVELOPMENT

12.2 WAISMAN BIOMANUFACTURING

12.20.1 COMPANY SNAPSHOT

12.20.2 PRODUCT PORTFOLIO

12.20.3 RECENT DEVELOPMENTS

13 QUESTIONNAIRE

14 RELATED REPORTS

表格列表

LIST OF TABLES

TABLE 1 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET, BY PRODUCT & SERVICES, 2019-2028 (USD MILLION)

TABLE 2 MIDDLE EAST AND AFRICA PRODUCTS IN VIRAL VECTOR PURIFICATION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 3 MIDDLE EAST AND AFRICA PRODUCTS IN VIRAL VECTOR PURIFICATION MARKET, BY PRODUCT & SERVICES, 2019-2028 (USD MILLION)

TABLE 4 MIDDLE EAST AND AFRICA SERVICES IN VIRAL VECTOR PURIFICATION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 5 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET, BY PURIFICATION TECHNIQUE, 2019-2028 (USD MILLION)

TABLE 6 MIDDLE EAST AND AFRICA CHROMATOGRAPHY IN VIRAL VECTOR PURIFICATION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 7 MIDDLE EAST AND AFRICA CHROMATOGRAPHY IN VIRAL VECTOR PURIFICATION MARKET, BY PURIFICATION TECHNIQUE, 2019-2028 (USD MILLION)

TABLE 8 MIDDLE EAST AND AFRICA DENSITY-GRADIENT ULTRACENTRIFUGATION IN VIRAL VECTOR PURIFICATION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 9 MIDDLE EAST AND AFRICA ULTRAFILTRATION IN VIRAL VECTOR PURIFICATION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 10 MIDDLE EAST AND AFRICA PRECIPITATION IN VIRAL VECTOR PURIFICATION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 11 MIDDLE EAST AND AFRICA TWO-PHASE EXTRACTION SYSTEMS IN VIRAL VECTOR PURIFICATION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 12 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 13 MIDDLE EAST AND AFRICA ADENO-ASSOCIATED VIRAL VECTORS IN VIRAL VECTOR PURIFICATION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 14 MIDDLE EAST AND AFRICA ADENOVIRAL VECTORS IN VIRAL VECTOR PURIFICATION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 15 MIDDLE EAST AND AFRICA ADENOVIRAL VECTORS IN VIRAL VECTOR PURIFICATION MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 16 MIDDLE EAST AND AFRICA LENTIVIRUS IN VIRAL VECTOR PURIFICATION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 17 MIDDLE EAST AND AFRICA RETROVIRAL VECTORS IN VIRAL VECTOR PURIFICATION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 18 MIDDLE EAST AND AFRICA RETROVIRAL VECTORS IN VIRAL VECTOR PURIFICATION MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 19 MIDDLE EAST AND AFRICA VACCINE VIRUS IN VIRAL VECTOR PURIFICATION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 20 MIDDLE EAST AND AFRICA OTHER IN VIRAL VECTOR PURIFICATION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 21 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET, BY WORKFLOW, 2019-2028 (USD MILLION)

TABLE 22 MIDDLE EAST AND AFRICA UPSTREAM PROCESSING IN VIRAL VECTOR PURIFICATION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 23 MIDDLE EAST AND AFRICA DOWNSTREAM PROCESSING IN VIRAL VECTOR PURIFICATION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 24 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET, BY SCALE OF OPERATION, 2019-2028 (USD MILLION)

TABLE 25 MIDDLE EAST AND AFRICA PRECLINICAL / CLINICAL IN VIRAL VECTOR PURIFICATION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 26 MIDDLE EAST AND AFRICA COMMERCIAL IN VIRAL VECTOR PURIFICATION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 27 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET, BY DELIVERY MODE, 2019-2028 (USD MILLION)

TABLE 28 MIDDLE EAST AND AFRICA IN VIVO IN VIRAL VECTOR PURIFICATION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 29 MIDDLE EAST AND AFRICA EX VIVO IN VIRAL VECTOR PURIFICATION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 30 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)

TABLE 31 MIDDLE EAST AND AFRICA GENETIC DISORDERS IN VIRAL VECTOR PURIFICATION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 32 MIDDLE EAST AND AFRICA GENETIC DISORDERS IN VIRAL VECTOR PURIFICATION MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)

TABLE 33 MIDDLE EAST AND AFRICA INFECTIOUS DISEASES IN VIRAL VECTOR PURIFICATION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 34 MIDDLE EAST AND AFRICA INFECTIOUS DISEASES IN VIRAL VECTOR PURIFICATION MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)

TABLE 35 MIDDLE EAST AND AFRICA VETERINARY DISEASE IN VIRAL VECTOR PURIFICATION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 36 MIDDLE EAST AND AFRICA CANCER IN VIRAL VECTOR PURIFICATION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 37 MIDDLE EAST AND AFRICA OTHER IN VIRAL VECTOR PURIFICATION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 38 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 39 MIDDLE EAST AND AFRICA GENE THERAPY IN VIRAL VECTOR PURIFICATION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 40 MIDDLE EAST AND AFRICA GENE THERAPY IN VIRAL VECTOR PURIFICATION MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 41 MIDDLE EAST AND AFRICA CELL THERAPY IN VIRAL VECTOR PURIFICATION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 42 MIDDLE EAST AND AFRICA VACCINOLOGY IN VIRAL VECTOR PURIFICATION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 43 MIDDLE EAST AND AFRICA ANTISENSE & RNAI IN VIRAL VECTOR PURIFICATION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 44 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 45 MIDDLE EAST AND AFRICA ACADEMIC/ RESEARCH INSTITUTES IN VIRAL VECTOR PURIFICATION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 46 MIDDLE EAST AND AFRICA PHARMACEUTICAL COMPANIES IN VIRAL VECTOR PURIFICATION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 47 MIDDLE EAST AND AFRICA CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION (CDMO) IN VIRAL VECTOR PURIFICATION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 48 MIDDLE EAST AND AFRICA BIOTECHNOLOGY COMPANIES IN VIRAL VECTOR PURIFICATION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 49 MIDDLE EAST AND AFRICA CONTRACT RESEARCH ORGANIZATIONS IN VIRAL VECTOR PURIFICATION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 50 MIDDLE EAST & AFRICA VIRAL VECTOR PURIFICATION MARKET, BY COUNTRY, 2021-2028 (USD MILLION)

TABLE 51 MIDDLE EAST & AFRICA VIRAL VECTOR PURIFICATION MARKET, BY PRODUCT & SERVICES, 2019-2028 (USD MILLION)

TABLE 52 MIDDLE EAST & AFRICA PRODUCTS IN VIRAL VECTOR PURIFICATION MARKET, BY PRODUCT & SERVICES, 2019-2028 (USD MILLION)

TABLE 53 MIDDLE EAST & AFRICA VIRAL VECTOR PURIFICATION MARKET, BY PURIFICATION TECHNIQUE, 2019-2028 (USD MILLION)

TABLE 54 MIDDLE EAST & AFRICA CHROMATOGRAPHY IN VIRAL VECTOR PURIFICATION MARKET, BY PURIFICATION TECHNIQUE, 2019-2028 (USD MILLION)

TABLE 55 MIDDLE EAST & AFRICA VIRAL VECTOR PURIFICATION MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 56 MIDDLE EAST & AFRICA RETROVIRAL VECTORS IN VIRAL VECTOR PURIFICATION MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 57 MIDDLE EAST & AFRICA ADENOVIRAL VECTORS IN VIRAL VECTOR PURIFICATION MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 58 MIDDLE EAST & AFRICA VIRAL VECTOR PURIFICATION MARKET, BY WORKFLOW, 2019-2028 (USD MILLION)

TABLE 59 MIDDLE EAST & AFRICA VIRAL VECTOR PURIFICATION MARKET, BY SCALE OF OPERATION, 2019-2028 (USD MILLION)

TABLE 60 MIDDLE EAST & AFRICA VIRAL VECTOR PURIFICATION MARKET, BY DELIVERY METHOD, 2019-2028 (USD MILLION)

TABLE 61 MIDDLE EAST & AFRICA VIRAL VECTOR PURIFICATION MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)

TABLE 62 MIDDLE EAST & AFRICA GENETIC DISORDERS IN VIRAL VECTOR PURIFICATION MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)

TABLE 63 MIDDLE EAST & AFRICA INFECTIOUS DISEASES IN VIRAL VECTOR PURIFICATION MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)

TABLE 64 MIDDLE EAST & AFRICA VIRAL VECTOR PURIFICATION MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 65 MIDDLE EAST & AFRICA GENE THERAPY IN VIRAL VECTOR PURIFICATION MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 66 MIDDLE EAST & AFRICA VIRAL VECTOR PURIFICATION MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 67 SOUTH AFRICA VIRAL VECTOR PURIFICATION MARKET, BY PRODUCT & SERVICES, 2019-2028 (USD MILLION)

TABLE 68 SOUTH AFRICA PRODUCTS IN VIRAL VECTOR PURIFICATION MARKET, BY PRODUCT & SERVICES, 2019-2028 (USD MILLION)

TABLE 69 SOUTH AFRICA VIRAL VECTOR PURIFICATION MARKET, BY PURIFICATION TECHNIQUE, 2019-2028 (USD MILLION)

TABLE 70 SOUTH AFRICA CHROMATOGRAPHY IN VIRAL VECTOR PURIFICATION MARKET, BY PURIFICATION TECHNIQUE, 2019-2028 (USD MILLION)

TABLE 71 SOUTH AFRICA VIRAL VECTOR PURIFICATION MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 72 SOUTH AFRICA RETROVIRAL VECTORS IN VIRAL VECTOR PURIFICATION MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 73 SOUTH AFRICA ADENOVIRAL VECTORS IN VIRAL VECTOR PURIFICATION MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 74 SOUTH AFRICA VIRAL VECTOR PURIFICATION MARKET, BY WORKFLOW, 2019-2028 (USD MILLION)

TABLE 75 SOUTH AFRICA VIRAL VECTOR PURIFICATION MARKET, BY SCALE OF OPERATION, 2019-2028 (USD MILLION)

TABLE 76 SOUTH AFRICA VIRAL VECTOR PURIFICATION MARKET, BY DELIVERY METHOD, 2019-2028 (USD MILLION)

TABLE 77 SOUTH AFRICA VIRAL VECTOR PURIFICATION MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)

TABLE 78 SOUTH AFRICA GENETIC DISORDERS IN VIRAL VECTOR PURIFICATION MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)

TABLE 79 SOUTH AFRICA INFECTIOUS DISEASES IN VIRAL VECTOR PURIFICATION MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)

TABLE 80 SOUTH AFRICA VIRAL VECTOR PURIFICATION MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 81 SOUTH AFRICA GENE THERAPY IN VIRAL VECTOR PURIFICATION MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 82 SOUTH AFRICA VIRAL VECTOR PURIFICATION MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 83 SAUDI ARABIA VIRAL VECTOR PURIFICATION MARKET, BY PRODUCT & SERVICES, 2019-2028 (USD MILLION)

TABLE 84 SAUDI ARABIA PRODUCTS IN VIRAL VECTOR PURIFICATION MARKET, BY PRODUCT & SERVICES, 2019-2028 (USD MILLION)

TABLE 85 SAUDI ARABIA VIRAL VECTOR PURIFICATION MARKET, BY PURIFICATION TECHNIQUE, 2019-2028 (USD MILLION)

TABLE 86 SAUDI ARABIA CHROMATOGRAPHY IN VIRAL VECTOR PURIFICATION MARKET, BY PURIFICATION TECHNIQUE, 2019-2028 (USD MILLION)

TABLE 87 SAUDI ARABIA VIRAL VECTOR PURIFICATION MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 88 SAUDI ARABIA RETROVIRAL VECTORS IN VIRAL VECTOR PURIFICATION MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 89 SAUDI ARABIA ADENOVIRAL VECTORS IN VIRAL VECTOR PURIFICATION MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 90 SAUDI ARABIA VIRAL VECTOR PURIFICATION MARKET, BY WORKFLOW, 2019-2028 (USD MILLION)

TABLE 91 SAUDI ARABIA VIRAL VECTOR PURIFICATION MARKET, BY SCALE OF OPERATION, 2019-2028 (USD MILLION)

TABLE 92 SAUDI ARABIA VIRAL VECTOR PURIFICATION MARKET, BY DELIVERY METHOD, 2019-2028 (USD MILLION)

TABLE 93 SAUDI ARABIA VIRAL VECTOR PURIFICATION MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)

TABLE 94 SAUDI ARABIA GENETIC DISORDERS IN VIRAL VECTOR PURIFICATION MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)

TABLE 95 SAUDI ARABIA INFECTIOUS DISEASES IN VIRAL VECTOR PURIFICATION MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)

TABLE 96 SAUDI ARABIA VIRAL VECTOR PURIFICATION MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 97 SAUDI ARABIA GENE THERAPY IN VIRAL VECTOR PURIFICATION MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 98 SAUDI ARABIA VIRAL VECTOR PURIFICATION MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 99 UAE VIRAL VECTOR PURIFICATION MARKET, BY PRODUCT & SERVICES, 2019-2028 (USD MILLION)

TABLE 100 UAE PRODUCTS IN VIRAL VECTOR PURIFICATION MARKET, BY PRODUCT & SERVICES, 2019-2028 (USD MILLION)

TABLE 101 UAE VIRAL VECTOR PURIFICATION MARKET, BY PURIFICATION TECHNIQUE, 2019-2028 (USD MILLION)

TABLE 102 UAE CHROMATOGRAPHY IN VIRAL VECTOR PURIFICATION MARKET, BY PURIFICATION TECHNIQUE, 2019-2028 (USD MILLION)

TABLE 103 UAE VIRAL VECTOR PURIFICATION MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 104 UAE RETROVIRAL VECTORS IN VIRAL VECTOR PURIFICATION MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 105 UAE ADENOVIRAL VECTORS IN VIRAL VECTOR PURIFICATION MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 106 UAE VIRAL VECTOR PURIFICATION MARKET, BY WORKFLOW, 2019-2028 (USD MILLION)

TABLE 107 UAE VIRAL VECTOR PURIFICATION MARKET, BY SCALE OF OPERATION, 2019-2028 (USD MILLION)

TABLE 108 UAE VIRAL VECTOR PURIFICATION MARKET, BY DELIVERY METHOD, 2019-2028 (USD MILLION)

TABLE 109 UAE VIRAL VECTOR PURIFICATION MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)

TABLE 110 UAE GENETIC DISORDERS IN VIRAL VECTOR PURIFICATION MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)

TABLE 111 UAE INFECTIOUS DISEASES IN VIRAL VECTOR PURIFICATION MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)

TABLE 112 UAE VIRAL VECTOR PURIFICATION MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 113 UAE GENE THERAPY IN VIRAL VECTOR PURIFICATION MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 114 UAE VIRAL VECTOR PURIFICATION MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 115 EGYPT VIRAL VECTOR PURIFICATION MARKET, BY PRODUCT & SERVICES, 2019-2028 (USD MILLION)

TABLE 116 EGYPT PRODUCTS IN VIRAL VECTOR PURIFICATION MARKET, BY PRODUCT & SERVICES, 2019-2028 (USD MILLION)

TABLE 117 EGYPT VIRAL VECTOR PURIFICATION MARKET, BY PURIFICATION TECHNIQUE, 2019-2028 (USD MILLION)

TABLE 118 EGYPT CHROMATOGRAPHY IN VIRAL VECTOR PURIFICATION MARKET, BY PURIFICATION TECHNIQUE, 2019-2028 (USD MILLION)

TABLE 119 EGYPT VIRAL VECTOR PURIFICATION MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 120 EGYPT RETROVIRAL VECTORS IN VIRAL VECTOR PURIFICATION MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 121 EGYPT ADENOVIRAL VECTORS IN VIRAL VECTOR PURIFICATION MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 122 EGYPT VIRAL VECTOR PURIFICATION MARKET, BY WORKFLOW, 2019-2028 (USD MILLION)

TABLE 123 EGYPT VIRAL VECTOR PURIFICATION MARKET, BY SCALE OF OPERATION, 2019-2028 (USD MILLION)

TABLE 124 EGYPT VIRAL VECTOR PURIFICATION MARKET, BY DELIVERY METHOD, 2019-2028 (USD MILLION)

TABLE 125 EGYPT VIRAL VECTOR PURIFICATION MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)

TABLE 126 EGYPT GENETIC DISORDERS IN VIRAL VECTOR PURIFICATION MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)

TABLE 127 EGYPT INFECTIOUS DISEASES IN VIRAL VECTOR PURIFICATION MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)

TABLE 128 EGYPT VIRAL VECTOR PURIFICATION MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 129 EGYPT GENE THERAPY IN VIRAL VECTOR PURIFICATION MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 130 EGYPT VIRAL VECTOR PURIFICATION MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 131 ISRAEL VIRAL VECTOR PURIFICATION MARKET, BY PRODUCT & SERVICES, 2019-2028 (USD MILLION)

TABLE 132 ISRAEL PRODUCTS IN VIRAL VECTOR PURIFICATION MARKET, BY PRODUCT & SERVICES, 2019-2028 (USD MILLION)

TABLE 133 ISRAEL VIRAL VECTOR PURIFICATION MARKET, BY PURIFICATION TECHNIQUE, 2019-2028 (USD MILLION)

TABLE 134 ISRAEL CHROMATOGRAPHY IN VIRAL VECTOR PURIFICATION MARKET, BY PURIFICATION TECHNIQUE, 2019-2028 (USD MILLION)

TABLE 135 ISRAEL VIRAL VECTOR PURIFICATION MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 136 ISRAEL RETROVIRAL VECTORS IN VIRAL VECTOR PURIFICATION MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 137 ISRAEL ADENOVIRAL VECTORS IN VIRAL VECTOR PURIFICATION MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 138 ISRAEL VIRAL VECTOR PURIFICATION MARKET, BY WORKFLOW, 2019-2028 (USD MILLION)

TABLE 139 ISRAEL VIRAL VECTOR PURIFICATION MARKET, BY SCALE OF OPERATION, 2019-2028 (USD MILLION)

TABLE 140 ISRAEL VIRAL VECTOR PURIFICATION MARKET, BY DELIVERY METHOD, 2019-2028 (USD MILLION)

TABLE 141 ISRAEL VIRAL VECTOR PURIFICATION MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)

TABLE 142 ISRAEL GENETIC DISORDERS IN VIRAL VECTOR PURIFICATION MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)

TABLE 143 ISRAEL INFECTIOUS DISEASES IN VIRAL VECTOR PURIFICATION MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)

TABLE 144 ISRAEL VIRAL VECTOR PURIFICATION MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 145 ISRAEL GENE THERAPY IN VIRAL VECTOR PURIFICATION MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 146 ISRAEL VIRAL VECTOR PURIFICATION MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 147 REST OF MIDDLE EAST & AFRICA VIRAL VECTOR PURIFICATION MARKET, BY PRODUCT & SERVICES, 2019-2028 (USD MILLION)

 

图片列表

LIST OF FIGURES

FIGURE 1 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: SEGMENTATION

FIGURE 2 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: DATA TRIANGULATION

FIGURE 3 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: DROC ANALYSIS

FIGURE 4 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: MIDDLE EAST AND AFRICA VS REGIONAL MARKET ANALYSIS

FIGURE 5 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: MULTIVARIATE MODELLING

FIGURE 7 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 8 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: DBMR MARKET POSITION GRID

FIGURE 9 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: MARKET APPLICATION COVERAGE GRID

FIGURE 11 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: SEGMENTATION

FIGURE 12 AVAILABILITY OF DIVERSE RANGE OF INNOVATIVE SOLUTIONS FOR VECTOR PURIFICATION IS DRIVING THE MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET IN THE FORECAST PERIOD OF 2021 TO 2028

FIGURE 13 PRODUCTS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET IN 2021 & 2028

FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET

FIGURE 15 ESTIMATED NUMBER OF NEW CASES IN MALE AND FEMALE (ALL AGE GROUP) WORLDWIDE IN 2018

FIGURE 1 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: BY PRODUCT & SERVICES, 2020

FIGURE 2 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: BY PRODUCT & SERVICES, 2021-2028 (USD MILLION)

FIGURE 3 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: BY PRODUCT & SERVICES, CAGR (2021-2028)

FIGURE 4 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: BY PRODUCT & SERVICES, LIFELINE CURVE

FIGURE 5 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: BY PURIFICATION TECHNIQUE, 2020

FIGURE 6 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: BY PURIFICATION TECHNIQUE, 2021-2028 (USD MILLION)

FIGURE 7 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: BY PURIFICATION TECHNIQUE, CAGR (2021-2028)

FIGURE 8 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: BY PURIFICATION TECHNIQUE, LIFELINE CURVE

FIGURE 9 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: BY TYPE, 2020

FIGURE 10 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: BY TYPE, 2021-2028 (USD MILLION)

FIGURE 11 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: BY TYPE, CAGR (2021-2028)

FIGURE 12 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: BY TYPE, LIFELINE CURVE

FIGURE 13 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: BY WORKFLOW, 2020

FIGURE 14 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: BY WORKFLOW, 2021-2028 (USD MILLION)

FIGURE 15 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: BY WORKFLOW, CAGR (2021-2028)

FIGURE 16 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: BY WORKFLOW, LIFELINE CURVE

FIGURE 17 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: BY SCALE OF OPERATION, 2020

FIGURE 18 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: BY SCALE OF OPERATION, 2021-2028 (USD MILLION)

FIGURE 19 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: BY SCALE OF OPERATION, CAGR (2021-2028)

FIGURE 20 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: BY SCALE OF OPERATION, LIFELINE CURVE

FIGURE 21 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: BY DELIVERY MODE, 2020

FIGURE 22 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: BY DELIVERY MODE, 2021-2028 (USD MILLION)

FIGURE 23 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: BY DELIVERY MODE, CAGR (2021-2028)

FIGURE 24 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: BY DELIVERY MODE, LIFELINE CURVE

FIGURE 25 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: BY DISEASE INDICATION, 2020

FIGURE 26 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: BY DISEASE INDICATION, 2021-2028 (USD MILLION)

FIGURE 27 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: BY DISEASE INDICATION, CAGR (2021-2028)

FIGURE 28 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: BY DISEASE INDICATION, LIFELINE CURVE

FIGURE 29 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: BY APPLICATION, 2020

FIGURE 30 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: BY APPLICATION, 2021-2028 (USD MILLION)

FIGURE 31 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: BY APPLICATION, CAGR (2021-2028)

FIGURE 32 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: BY APPLICATION, LIFELINE CURVE

FIGURE 33 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: BY END USER, 2020

FIGURE 34 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: BY END USER, 2021-2028 (USD MILLION)

FIGURE 35 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: BY END USER, CAGR (2021-2028)

FIGURE 36 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: BY END USER, LIFELINE CURVE

FIGURE 37 MIDDLE EAST & AFRICA VIRAL VECTOR PURIFICATION MARKET: SNAPSHOT (2020)

FIGURE 38 MIDDLE EAST & AFRICA VIRAL VECTOR PURIFICATION MARKET: BY COUNTRY (2020)

FIGURE 39 MIDDLE EAST & AFRICA VIRAL VECTOR PURIFICATION MARKET: BY COUNTRY (2021 & 2028)

FIGURE 40 MIDDLE EAST & AFRICA VIRAL VECTOR PURIFICATION MARKET: BY COUNTRY (2020 & 2028)

FIGURE 41 MIDDLE EAST & AFRICA VIRAL VECTOR PURIFICATION MARKET: BY TYPE (2021-2028)

FIGURE 42 MIDDLE EAST AND AFRICA VIRAL VECTOR PURIFICATION MARKET: COMPANY SHARE 2020 (%)

 

查看详细信息 Right Arrow

研究方法

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

可定制

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Frequently Asked Questions

The Middle East and Africa Viral Vector Purification Market is projected to grow at a CAGR of 12.4% during the forecast period by 2028.
The future market value of the Middle East and Africa Viral Vector Purification Market is expected to reach USD 22.17 million by 2028.
The major players in the Middle East and Africa Viral Vector Purification Market are Applied Biological Materials Inc., Creative Biolabs, Bio-Rad Laboratories, Inc., Merck KGaA, Agilent Technologies, Inc., Thermo Fisher Scientific Inc., uniQure N.V., etc.
The countries covered in the Middle East and Africa Viral Vector Purification Market are Saudi Arabia, South Africa, UAE, Israel, Egypt and rest of Middle East and Africa.
On the basis of application, the Middle East and Africa Viral Vector Purification Market is segmented into antisense & RNAi, gene therapy, cell therapy and vaccinology.